SUPPLEMENTARY MATERIAL

Supplementary Table 1. Bias assessment

Authors	Y. of publ.	Patient selection		Index text		Reference standard		Time and flow
		Risk of bias	Concerns about applicability	Risk of bias	Concerns about applicability	Risk of bias	Concerns about applicability	Risk of bias
Imai et al.	2005	Low	Low	High	High	High	High	Low
Jovin et al.	2005	Low	Low	High	High	High	High	Low
Dabitz et al.	2007	Low	Low	High	High	High	High	Low
Papanagiotou et al.	2011	Low	Low	Low	Low	Low	Low	Low
Hajdukova et al.	2013	Low	High	High	High	High	High	Low
Dalyiai et al.	2013	Low	Unclear	High	High	High	High	Low
Mpotsaris et al.	2013	Low	Low	Low	Low	Low	Low	Low
Stampfl et al.	2014	Low	Low	Low	Low	Unclear	Low	Low
Tütüncü et al.	2014	Low	Low	Low	Low	Low	Low	Low
Lescher et al.	2014	Low	Low	Low	Low	Low	Low	Low
Heck et al.	2014	Low	Low	Low	Low	Low	Low	Low
Cohen et al.	2014	Low	Low	Low	Low	Low	Low	Low
Lockau et al.	2014	Low	Low	Low	Low	Low	Low	Low
Spiotta et al.	2014	Low	Low	High	Unclear	Low	Low	Low
Dababneh et al.	2014	Low	Low	High	Unclear	Low	Low	Low
Choi et al.	2014	Low	Low	Low	Low	Low	Low	Low
Behme et al.	2015	Low	Low	Low	Low	Low	Low	Low
Maurer et al.	2015	Low	Low	Low	Low	Low	Low	Low
Puri et al.	2015	Low	Low	Low	Low	Low	Low	Low

Steglich-Arnholm et al.	2015	Low	Low	Low	Low	Low	Low	Low
Yoon et al.	2015	Low	Low	Low	Low	Low	Low	Low
de Lucena et al.	2015	Low	Low	Low	Low	Low	Low	Low
Son et al.	2015	Low	Low	Low	Low	Low	Low	Low
Grigoryan	2016	Low	Low	High	Unclear	Low	Low	Low
Fahed	2016	Low	Low	High	Unclear	Low	Low	Low
Rangel-Castilla et al.	2017	Low	Low	Low	Low	Low	Low	Low
Sallustio et al.	2017	Low	Low	Low	Low	Low	Low	Low
Akpinar et al.	2017	Low	Low	Low	Low	Low	Low	Low
Mpotsaris et al.	2017	Low	Low	Low	Low	Low	Low	Low
Al-Mufti et al.	2017	Low	Low	Low	Low	Low	Low	Low
Mehta et al.	2018	Low	Low	High	Unclear	Low	Low	Low
Li et al.	2018	Low	Low	Low	Low	Low	Low	Low
Bartolini et al.	2018	Low	Low	Low	Low	Low	Low	Low
Sadeh-Gonik et al.	2018	Low	Low	High	Unclear	Low	Low	Low
Papanagiotou et al.	2018	Low	Low	Low	Low	Low	Low	Low
Maus et al.	2018	Low	Low	Low	Low	Low	Low	Low
Eker et al.	2018	Low	Low	Low	Low	Low	Low	Low
Wallocha et al.	2019	Low	Low	Low	Low	Low	Low	Low
Kang et al.	2019	Low	Low	Low	Low	Low	Low	Low
Jadhav et al.	2019	Low	Low	Low	Low	Low	Low	Low
Kim et al.	2020	Low	Low	Low	Low	Low	Low	Low
Garg et al.	2021	Low	Low	High	Unclear	Low	Low	Low

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J NeuroIntervent Surg

Bracco et al.	2021	Low	Low	High	Unclear	Low	Low	Low
Li et al.	2021	Low	Low	Low	Low	Low	Low	Low
Cirillo et al.	2021	Low	Low	Low	Low	Low	Low	Low
Pop et al.	2022	Low	Low	Low	Low	Low	Low	Low

Supplementary Figure 1. Funnel-plot for publication bias in studies included in meta-analysis for primary outcome.

No publication bias emerges from linear regression test for funnel plot asymmetry (p=0.53).

Supplementary Figure 2. Meta-analysis of proportions for mRS 0-2 in eCAS studies.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

J NeuroIntervent Surg

Supplementary Figure 3. Meta-analysis of proportions for mRS 0-2 in no stenting studies.

Source	Proportion (95% CI)
Akpinar 2017	0.67 [0.38; 0.88]
Bracco 2021	0.39 [0.29; 0.49]
Cirillo 2021	0.60 [0.41; 0.77]
Eker et al. 2018	0.55 [0.32; 0.76]
Fahed 2016	0.45 [0.28; 0.64]
Grigoryan 2016	0.42 [0.25; 0.61]
Jadhav et al. 2019	0.42 [0.30; 0.55]
Kang et al. 2019	0.59 [0.36; 0.79]
Kim et al. 2020	0.26 [0.09; 0.51]
Lescher 2014	0.37 [0.20; 0.56]
Li 2018	0.50 [0.26; 0.74]
Li et al. 2021	0.56 [0.40; 0.70]
Mpotsaris 2013	0.33 [0.16; 0.55]
Papanagiotou 2018	0.41 [0.34; 0.49]
Tütüncü 2014	0.50 [0.19; 0.81]
Wallocha et al. 2019	0.57 [0.29; 0.82]
Total	0.45 [0.40; 0.50]

Heterogeneity: $\chi^2_{15} = 18.16$ ($P = .25$), $I^2 = 17\%$

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J NeuroIntervent Surg

Supplementary Figure 4. Evolution over time of the comparison for mRS 0-2 depending on treatment paradigm.

Supplementary Figure 5. Meta-analysis of proportions for recurrent stroke in eCAS group (above) and no stenting group (below).

Supplementary Figure 6. Embolization to new territories depending on treatment paradigm.


Study	eCAS Events	Total	no stenting Events	Total	Odds Ratio	OR	95%-CI	Weight
Bracco 2021	36	132	2	95		17.44	[4.08; 74.50]	33.5%
Li 2018	3	19	5	18		0.49	[0.10; 2.43]	32.7%
Li 2021	3	30	10	45		0.39	[0.10; 1.55]	33.8%
Random effects model	**42**	**181**	**17**	**158**		**1.50**	**[0.12; 19.39]**	**100.0%**

Heterogeneity: $I^2 = 89\%$, $\tau^2 = 4.5527$, $p < 0.01$

favors eCAS   against eCAS

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J NeuroIntervent Surg

Supplementary Figure 7. Meta-analysis of proportions for restenosis after eCAS and no stenting

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J NeuroIntervent Surg

Supplementary Figure 8. Successful reperfusion (TICI 2b-3) prevalence depending on antegrade (stenting first) vs retrograde (mechanical thrombectomy, MT, first) in eCAS group.

Supplementary Figure 9. mRS 0-2 prevalence depending on antegrade (stenting first) vs retrograde (mechanical thrombectomy, MT, first) in eCAS group.

Supplementary Figure 10. sICH prevalence depending on use of antithrombotics in eCAS group.

Supplementary Figure 11. mRS 0-2 prevalence depending on use of antithrombotics in eCAS group.